University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND, USA.
Anticancer Res. 2009 Dec;29(12):5143-8.
Epidemiological data on the association between statin use and risk of breast cancer among overweight or obese postmenopausal women who have never used hormone therapy (HT) is limited.
A hospital-based case-control study was conducted in Fargo, ND, USA. Cases were overweight or obese, postmenopausal White women without a history of HT use who were newly diagnosed with breast cancer. Controls were White women without clinical cancer who were seen at the same hospital for an annual physical examination.
From a patient population aged 55 to 81 years old, data were obtained on 95 cases and 94 controls. Overall, there was no association between the use of statins and breast cancer risk odds ratio (OR)=1.3 (95% confidence interval (CI) 0.7-2.5). However, risk varied by hormone receptor status. Compared to non-users, obese women who used hydrophobic statins had an elevated risk of progesterone receptor-negative (PR(-)) breast cancer OR=4.0 (95% CI 1.2-13.8), but not of tumors with other hormone receptor profiles. The risk for breast cancer was also significantly increased among overweight women who used hydrophobic statins for less than or equal to 4 years OR=4.1 (95% CI 1.2-14.4).
This observational study found an increased risk of breast cancer related to duration of statins use and PR(-) among postmenopausal women.
在从未使用过激素疗法（HT）的超重或肥胖绝经后妇女中，关于他汀类药物使用与乳腺癌风险之间的关联的流行病学数据有限。
在美国北达科他州法戈市进行了一项基于医院的病例对照研究。病例为超重或肥胖、绝经后、未使用过 HT 的白人女性，且新诊断为乳腺癌。对照组为白人女性，无临床癌症，在同一家医院进行年度体检。
从年龄在 55 至 81 岁的患者人群中，获得了 95 例病例和 94 例对照的数据。总体而言，他汀类药物的使用与乳腺癌风险之间没有关联，比值比（OR）=1.3（95%置信区间（CI）0.7-2.5）。然而，风险因激素受体状态而异。与非使用者相比，使用疏水性他汀类药物的肥胖女性孕激素受体阴性（PR(-)）乳腺癌的风险升高，比值比（OR）=4.0（95%置信区间（CI）1.2-13.8），但对于其他激素受体谱的肿瘤则不然。使用疏水性他汀类药物少于或等于 4 年的超重女性患乳腺癌的风险也显著增加，比值比（OR）=4.1（95%置信区间（CI）1.2-14.4）。
这项观察性研究发现，绝经后妇女使用他汀类药物的时间和孕激素受体阴性（PR(-)）与乳腺癌风险增加有关。
